Thomas Renaud

1.2k total citations · 1 hit paper
70 papers, 667 citations indexed

About

Thomas Renaud is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Thomas Renaud has authored 70 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 25 papers in Oncology and 16 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Thomas Renaud's work include Multiple Myeloma Research and Treatments (29 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and CAR-T cell therapy research (9 papers). Thomas Renaud is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and CAR-T cell therapy research (9 papers). Thomas Renaud collaborates with scholars based in United States, France and Spain. Thomas Renaud's co-authors include Florence Jusot, Jaszianne Tolbert, Brandi Hilder, Tara Masterson, Josselin Thuilliez, Andrew Street, Rachel Kobos, Michela Campagna, Paula Rodríguez‐Otero and Deeksha Vishwamitra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Thomas Renaud

60 papers receiving 651 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Renaud United States	16	281	271	195	123	112	70	667
J. Leonard Lichtenfeld United States	15	86 0.3×	282 1.0×	114 0.6×	62 0.5×	31 0.3×	24	679
Hira Mian Canada	15	346 1.2×	329 1.2×	204 1.0×	19 0.2×	37 0.3×	109	668
E. A. Lyons United States	8	171 0.6×	106 0.4×	46 0.2×	65 0.5×	30 0.3×	15	549
Clarissa Mathias Brazil	10	64 0.2×	409 1.5×	47 0.2×	48 0.4×	46 0.4×	32	749
Nicola Bienz United Kingdom	10	134 0.5×	115 0.4×	65 0.3×	64 0.5×	20 0.2×	15	456
Sarah Côté United States	8	301 1.1×	195 0.7×	244 1.3×	67 0.5×	13 0.1×	26	496
Cara Angelotta United States	9	223 0.8×	124 0.5×	71 0.4×	39 0.3×	17 0.2×	16	525
Rabbia Siddiqi Pakistan	11	81 0.3×	87 0.3×	25 0.1×	63 0.5×	46 0.4×	41	439
Lena E. Winestone United States	14	114 0.4×	144 0.5×	31 0.2×	86 0.7×	8 0.1×	71	570
Thierry Calvez France	15	622 2.2×	32 0.1×	150 0.8×	40 0.3×	70 0.6×	30	897

Countries citing papers authored by Thomas Renaud

Since Specialization

Citations

This map shows the geographic impact of Thomas Renaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Renaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Renaud more than expected).

Fields of papers citing papers by Thomas Renaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Renaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Renaud. The network helps show where Thomas Renaud may publish in the future.

Co-authorship network of co-authors of Thomas Renaud

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Renaud. A scholar is included among the top collaborators of Thomas Renaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Renaud. Thomas Renaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harvey, R. Donald, et al.. (2025). Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab: Highlights From Pharmacists’ Perspectives. Journal of the Advanced Practitioner in Oncology. 16(7). 1–16.

Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S240–S240. 5 indexed citations

Schinke, Carolina, Cyrille Touzeau, Monique C. Minnema, et al.. (2024). P-098 Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S99.

Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S100. 1 indexed citations

Morillo, Daniel, Carmen Martínez Chamorro, Luciano J. Costa, et al.. (2024). P-058 Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S74–S75. 1 indexed citations

Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S561–S562. 9 indexed citations

Schinke, Carolina, Ravi Vij, Sundar Jagannath, et al.. (2024). P-077 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S86–S86. 2 indexed citations

Estelle, F., et al.. (2024). Cerebral net uptake of lactate contributes to neurological injury after experimental cardiac arrest in rabbits. Scientific Reports. 14(1). 24600–24600.

Hilder, Brandi, Tara Masterson, Jaszianne Tolbert, et al.. (2024). Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model. Targeted Oncology. 19(6). 965–979. 1 indexed citations

10.

Rodríguez‐Otero, Paula, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, et al.. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer Journal. 14(1). 24–24. 51 indexed citations breakdown →

11.

Rogers, Stephanie, Lisa O’Rourke, Kathleen Gray, et al.. (2024). Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma. Seminars in Oncology Nursing. 40(5). 151712–151712. 3 indexed citations

12.

Jusot, Florence, et al.. (2024). Did the COVID-19 pandemic reshape equity in healthcare use in Europe?. Social Science & Medicine. 358. 117194–117194. 2 indexed citations

13.

Kaufman, Jonathan L., Saad Z. Usmani, Jesús F. San Miguel, et al.. (2019). Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1866–1866. 28 indexed citations

14.

Saillour-Glénisson, F., Laëtitia Huiart, Emmanuel Langlois, et al.. (2017). Protocole of a controlled before-after evaluation of a national health information technology-based program to improve healthcare coordination and access to information. BMC Health Services Research. 17(1). 297–297. 6 indexed citations

15.

Kobos, Rachel, Neerav Shukla, Thomas Renaud, et al.. (2013). High-Dose Cyclophosphamide for the Treatment of Refractory T-Cell Acute Lymphoblastic Leukemia in Children. Journal of Pediatric Hematology/Oncology. 36(5). e265–e270. 6 indexed citations

16.

Street, Andrew, et al.. (2012). HOW WELL DO DIAGNOSIS‐RELATED GROUPS EXPLAIN VARIATIONS IN COSTS OR LENGTH OF STAY AMONG PATIENTS AND ACROSS HOSPITALS? METHODS FOR ANALYSING ROUTINE PATIENT DATA. Health Economics. 21(S2). 6–18. 47 indexed citations

17.

Renaud, Thomas, et al.. (2009). RESICARD: East Paris network for the management of heart failure: Absence of effect on mortality and rehospitalization in patients with severe heart failure admitted following severe decompensation. Archives of cardiovascular diseases. 102(1). 29–41. 13 indexed citations

18.

Renaud, Thomas, et al.. (2008). Impact des pratiques médicales sur le coût de prise en charge du cancer. Le cas du cancer du côlon en Île-de-France. Cairn.info. Vol. 39(4). 283–295. 2 indexed citations

19.

Heijink, Richard, et al.. (2008). Cost of illness: An international comparison. Health Policy. 88(1). 49–61. 25 indexed citations

20.

Fairley, Temeika L., Thomas Renaud, & Jan E. Conn. (2000). Effects of Local Geographic Barriers and Latitude on Population Structure in <I>Anopheles punctipennis</I> (Diptera: Culicidae). Journal of Medical Entomology. 37(5). 754–760. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact